Efficacy of levosimendan in the treatment of pulmonary heart disease patients with heart failure

VernacularTitle:左西孟旦治疗慢性肺源性心脏病并心力衰竭疗效观察
Author: Yuefan LI ; Weiyong ZHU
Publication Type:Journal Article
Keywords: Levosimendan; Heart disease,pulmonary origin; Heart failure; Natriuretic peptide,type B
From: Chinese Journal of Primary Medicine and Pharmacy 2016;23(6):894-896,897
CountryChina
Language:Chinese
Abstract: Objective To observe the effect of levosimendan in the treatment of pulmonary heart disease patients with heart failure.Methods 60 patients were randomly divided into treatment group and control group.The treatment group used levosimendan.The control group used digitalis.We observed the NT -PROBNP, echocardio-graphic and clinical efficacy.Adverse drug reactions were observed too.Results The significantly effect of the treat-ment group was 22 cases(73%),and effective was 8 cases (27%).The significant effect of the control group was 14 cases (43%),and effective was 16 cases (57%).The levels of NT-PROBNP and pulmonary artery pressure in the treatment group were ( 416 ±311 ) pg/mL, ( 51 ±9 ) mmHg after 1 month treatment, which in the control group were (1 516 ±250) ng/mL,(57 ±10) mmHg.The efficacy of the treatment group was better than the control group (χ2 =4.44,P<0.05),the levels of NT-PROBNP and pulmonary artery pressure were lower(t=15.10,2.44,all P<0.05).Conclusion The levosimendan had effects on the pulmonary heart disease patients with heart failure.